Amrutanjan Health Care Limited has fixed September 11, 2026, as the record date for the payment of its final dividend for the financial year 2025-26. This announcement determines which shareholders are eligible to receive the payout, establishing a clear cutoff for ownership verification. The declaration ensures that investors holding shares on or before this date will receive the declared dividend amount, subject to standard corporate action processing timelines.

The company notified the National Stock Exchange of India Limited and BSE Limited of this decision pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The filing confirms that eligibility is based on the register of members maintained by the company and the beneficial ownership details provided by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).

Key Dates and Details

Shareholders are advised to ensure their holdings are reflected in their demat accounts prior to the record date to secure entitlement. Any transfers or transactions occurring after the close of business on September 11, 2026, will not qualify for this specific dividend payment cycle.

What the Numbers Show

While the specific dividend per share amount was not disclosed in this particular regulatory filing, the establishment of a definitive record date signals the completion of the board’s approval process for the FY25-26 final distribution. For investors, the critical factor is maintaining continuous ownership through September 11, 2026, as any sale of shares after this date does not affect eligibility, whereas purchases made after this date will not carry the dividend right.

Amrutanjan Health Care Limited (AHCL) reported a net profit of ₹4.37 crore for the quarter ended June 30, 2026 (Q1FY27), a decline of 47.7% from ₹8.31 crore in the corresponding period of FY26. While revenue from operations grew 9.5% year-on-year to ₹102.97 crore, profitability was significantly impacted by rising operational costs and a one-time exceptional expense related to a lease rent settlement.

The Board of Directors approved the unaudited financial results on August 11, 2026, following a review by the Audit Committee and a limited review report issued by statutory auditors B S R & Co. LLP. The company also announced its 89th Annual General Meeting (AGM) scheduled for September 23, 2026, via video conference. The record date for determining shareholder eligibility for voting and final dividend payment has been fixed as September 11, 2026.

Financial Performance

Revenue from operations increased to ₹10,296.88 lakh in Q1FY27 from ₹9,404.57 lakh in Q1FY26. However, total expenses rose sharply to ₹10,678.36 lakh from ₹9,847.31 lakh in the prior year. The profit before tax stood at ₹6.07 crore, down from ₹11.29 crore in Q1FY26, primarily due to the exceptional item and higher finance costs.

The net profit after tax for the quarter was ₹4.37 crore, compared to ₹8.31 crore in Q1FY26. Basic earnings per share fell to ₹1.51 from ₹2.87 in the previous year’s same quarter.

Exceptional Items and Segment Performance

A key drag on profitability was an exceptional item of ₹20.28 lakh, representing the additional cost settled with the Tamil Nadu HR & CE Department regarding retrospective lease rent revisions. This follows a legal dispute where the High Court of Judicature, Madras, upheld the fair rent determination, leading to a final settlement in August 2026.

Segment-wise, OTC Products remained the largest revenue contributor at ₹57.26 crore, up slightly from ₹56.97 crore in Q1FY26. Women’s Hygiene & Personal Care revenue grew strongly to ₹36.36 crore from ₹28.61 crore. However, this segment recorded a loss of ₹2.88 crore, compared to a profit of ₹1.49 lakh in the prior year. Beverages revenue rose to ₹8.64 crore from ₹7.78 crore, though it incurred a loss of ₹12.60 lakh.

What the Numbers Show

The divergence between top-line growth and bottom-line contraction highlights margin pressure across key segments. While OTC Products maintained healthy segment results of ₹9.87 crore, the losses in Women’s Hygiene & Personal Care and Beverages segments widened, offsetting gains. Additionally, the recognition of the ₹20.28 lakh exceptional lease rent cost underscores the financial impact of prolonged regulatory disputes, suggesting that future earnings may remain sensitive to such non-operational liabilities unless resolved proactively.